Background: Neoadjuvant chemotherapy (NACT) has been recognized as a reliable therapeutic strategy in patients with unresectable advanced epithelial ovarian cancer (EOC). The molecular events leading to platinum (Pt) response in NACT settings have hitherto not been explored. In the present work, longitudinal changes of miRNA expression profile were investigated to identify miRNA families with prognostic role in high-grade serous EOC patients who received the NACT regimen.
neoadjuvant chemotherapy (NACT) has emerged as a reliable therapeutic strategy. In particular, Pt-based NACT appears an attractive treatment option in women with extensive tumor burden since the vast majority of patients experience a relevant tumor shrinkage which allows complete interval debulking surgery (IDS) to be conducted after three to four courses of NACT. However, ∼15%-20% of patients with advanced EOC do not respond to NACT [4] and present with progressively resistant disease ultimately dying within a few months after the initial diagnosis. These changes in the clinical response to chemotherapy probably mirror changes in the biology of tumor cells, a phenomenon known as 'temporal heterogeneity', which has been poorly investigated till now in HGS-EOC, since second surgery is uncommon in clinical practice.
Our group has recently dissected some features of temporal heterogeneity of EOC through the analysis of a cohort of patients from whom matched tumor biopsies were available at the time of primary surgery, before any treatment, and at time of relapse, after intervention with different lines of Pt-based chemotherapy [5] . We observed that cells from relapsed tumors had activated a transcriptional program led by transforming growth factor (TGF)-β and miR-181a-5p, which ultimately resulted in the transition from an epithelial to a mesenchymal state [6, 7] . Targeted re-sequencing analysis of genes involved in mechanisms controlling tumor cell growth, cell signaling and drug sensitivity showed that only 2% of somatic mutations observed at primary surgery were concordant in matched tumor biopsies from the same patients. Genomic and transcriptomic data suggest that the molecular portrait of cells from tumors of stage III-IV EOC at relapse, after one or more rounds of chemotherapy differ largely from that obtained at primary surgery, before chemotherapy [5] .
The discovery of reliable biomarkers to predict response to Ptbased neoadjuvant therapy (NACT) and/or overall survival (OS) and progression-free survival (PFS) requires to identify first those genetic lesions that persist over time during therapy and that might confer a selective growth advantages to tumor cells.
In this study, we took advantage of a unique and homogenous cohort of tumor biopsies taken from patients who underwent NACT regimen, and from whom matched biopsies were available at initial laparoscopy surgery, before chemotherapy and at IDS after four cycles of Pt-based therapy. These samples allowed us two novel types of insights, first into changes in microRNA (miRNA) expression profiles related to mechanisms of response to carboplatin and taxol therapy, and second into any association between the expression of specific miRNAs and either patients' response to NACT or prognosis.
patients and methods
We retrospectively assessed 82 HGS-EOC patients, admitted between January 2004 and November 2011 at the Gynecologic Oncology Unit of the Catholic University of the Sacred Heart in Rome. Patients received an initial laparoscopic evaluation, with the assessment of Fagotti's score [8] , and once judged unsuitable for optimal debulking surgery-due to the high tumor dissemination [9] -they were treated with NACT followed by IDS. The study has been carried out following the Declaration of Helsinki; the local scientific ethical committees approved the tumor sample collection and usage.
Written informed consent was obtained from all patients. The study received the Institutional Review Board approval.
results

study design and patient characteristics
To assess at which degree NACT can modify the tumor miRNA landscape, analysis was carried out in a matched cohort of tumor biopsies taken from patients receiving NACT at initial laparoscopic exploration and at the time of IDS. The use of matched tumor biopsies provides the unique advantage of allowing identification of mechanisms of chemotherapy resistance characterized by similar features, irrespective of individual genetic variation. To further minimize parameters introducing variation, well-characterized stage III-IV tumors of the commonest histological subtype (serous papillary adenocarcinoma, 86.7%) and tumor grade (G3, 85.4%) were selected for the study. Histopathological and clinical features are summarized in Table 1 . The median age at diagnosis was 62.5 years, with a median follow-up of 31 months; 44% of patients were alive and progression-free at the time of the last follow-up. All of them received the same schedule of Pt-based NACT (carboplatin AUC 5 plus paclitaxel 175 mg/m 2 , every 3 weeks) with only some differences in term of duration of NACT regimen. In particular, we administered three cycles of NACT in 15 women (18.3%), and four cycles in 67 patients (81.7%). Recurrent disease was observed in the vast majority of patients (86.6%). Among them, 33% had a platinum-free interval (PFI) of >12 months and were therefore potentially sensitive to second-line Pt-based chemotherapy. Forty percent had a PFI of <6 months and were considered resistant to second-line Pt-based therapy, and 26.8% presented with a PFI between 6 months and 1 year and were considered partially sensitive. According to the Cox proportional hazard model analysis (Table 1) residual tumor after IDS (>1 cm) and PFI were significantly associated (P < 0.05) with both OS and PFS, whereas partial clinical response to NACT was associated to PFS only (P = 0.04).
miRNA landscape analysis
To identify the entire repertoire of miRNAs expressed in patients with stage III/IV EOC, we conducted microarray analyses. Initially, similarity across samples was investigated by unsupervised cluster analysis on the expression values of 457 miRNAs identified by miRNA landscape analysis at both initial laparoscopic biopsies and at IDS. The cluster depicted in Figure 1 (and reported in full scale in supplementary Figure S1 , available at Annals of Oncology online) allowed unambiguous division of samples into two branches: branch I (green, on the left) composed of 57 biopsies and branch II (blue, on the right) composed of 107 biopsies (supplementary Table S1 , available at Annals of Oncology online). There was no evidence of any association between these groups and survival measures, OS or PFS (data not shown). Next, we investigated whether initial laparoscopic samples and IDS biopsies from the same patient clustered close to each other or were intermingled across the two main branches of the cluster. Branch I was significantly enriched in initial laparoscopic biopsies (P = 0.0001), whereas branch II was enriched in IDS biopsies (supplementary Table S1 , available at Annals of Oncology online).
These results are consistent with the hypothesis that tumor cells exposed to carboplatin plus taxol rapidly undergo dynamic molecular changes, so that several molecular features characterizing the tumor at primary surgery are modified by therapeutic intervention.
selection of miRNA families associated with modulation of platinum sensitivity Next, matched tumor samples were analyzed for those miRNAs whose expression levels were either comparable between IDS and initial laparoscopic evaluation (−1.5<fold change<1.5, referred from now as CEM, i.e. comparable expressed miRNA) or different between the two groups (−1.5>fold change>1.5, referred from now on as DEM, i.e. differentially expressed miRNAs). We identified 369 miRNAs, 256 of which were CEM, and 113 of which were DEM (67 with a fold change>1.5 and 46 with a fold change<−1.5, supplementary Table S2 , available at Annals of Oncology online). Unsupervised cluster analysis (supplementary Figure S2 , available at Annals of Oncology online) depicted a complex and heterogeneous picture, suggesting that, despite the homogenous clinic-histological features and In contrast, DEM with a fold change<−1.5 are those miRNAs whose expression decreased in IDS versus initial laparoscopic evaluation, are probably involved in mechanism of cellular sensitivity and thus were excluded from downstream analysis. Applying this criterion, only 323 among the 369 miRNAs were selected for downstream analysis. Selected miRNAs were not scattered across the entire miRNome, but belonged to specific families. On the basis of their role in resistance against Pt as reported in the literature [10, 11] , we focused our attention on five miRNA families: miR-199, miR-181, let-7, miR-29 and miR-30 ( Table 2) .
correlation of miRNA expression with clinical parameters
To investigate the potential correlation of five selected miRNAs families with clinical variables, we first validated microarray signatures by qRT-PCR. Data reported in Table 2 and in supplementary Figure S3 , available at Annals of Oncology online, confirmed the robustness of our gene expression analysis, and thus worthy of downstream analysis. Table 2 shows that among the miR-199 family members, miR-199a-3p and miR-199a-5p were associated with OS and PFS (P < 0.005), whereas miR-199b-5p was associated with OS only. Among the let-7 family members, let-7a-5p was associated with PFS (P ≤ 0.01), whereas let-7g-5p was associated with OS (P = 0.04) and PFS (P = 0.01). No correlation was found for the other let-7 family members. As to the miR-181 family, miR-181a-5p had a strong association with OS (P = 5.8 e −7 ) and PFS (P = 8.9 e −9 ). None of the members of the miR-29 and miR-30 families were associated with OS or PFS ( Table 2 ). Figure 2 shows survival plots for the prognostic groups identified by miR-199a-3p, miR-199a-5p, let-7g-5p, miR-181a-5p.
To examine the clinical relevance of the above selected four miRNAs, we analyzed their expression in patients tumors with different PFI or residual tumor after debulking surgery ( Figure  3) . The results suggest that tumor biopsies of patients with PFI <6 months, which is clinically defined as resistant to second-line Pt-based chemotherapy, presented with higher expression levels of miR-181a-5p (P < 0.001), miR-199a-5p (P = 0.004) and miR199a-3p (P = 0.003) than patients with PFI between 6 and 12 months, which are clinically defined as partially sensitive to second-line Pt-based therapy or patients with PFI of >12 months ( Figure 3A ). No differences were observed for let-7g-5p. Furthermore, tumor biopsies taken from patients with residual tumor tissue after IDS of >1 cm displayed higher expression levels of miR-181a-5p (P < 0.0001), miR-199a-5p (P < 0.001) and miR199a-3p (P = 0.01) than samples from the patients who lacked residual tumor or had residual tumor after IDS of <1 cm ( Figure 3B ). No differences were observed for let-7g-5p.
correlation of TGF-β pathway activation with prognosis
We have previously demonstrated that the expression of hsamiR-181a-5p and Smad2 phosphorylation (P-Smad2), a marker of TGF-β pathway activation, stratifies patients in terms of risk of relapse and OS in a cohort of HGS-EOC [7] . In the light of these findings, we assessed levels of P-Smad2 in this NACT cohort. Figure 4A shows representative immunohistochemistry (IHC) staining for P-Smad2. Staining intensity and nuclear localization of P-Smad2 were not homogenous but varied among patients. Immuno-histochemistry scores in the patients' cohort ranged from 0 to 100, with a median of 60. Box plots (supplementary Figure S4 , available at Annals of Oncology online) suggest that tumor biopsies taken from patients with PFI <6 months displayed more abundant nuclear P-Smad2 than biopsies obtained from patients with PFI >6 months. Instead, PSmad2 levels were not different among patients with residual tumor <1 cm or >1 cm after debulking surgery. Figure 4B (upper panels) reports Kaplan-Meier (KM) curves plotting OS and PFS against median tumor P-Smad2 histochemistry scores calculated for each patient. Data show a significant enrichment in P-Smad2, in patients who relapse within 20 months from the end of chemotherapy [P < 0.001; odds ratio (OR) = 1.4; 95% confidence interval (CI) 1.1-1.9] and have a short survival (P < 0.001; OR = 2.2; 95% CI 1.4-3.6). Intriguingly, KM curves of survival against concomitant expression of miR181a-5p and immune score of P-Smad-2, stratified patients for risk of relapse and survival ( Figure 4B, lower panels) . This stratification was statistically more significant than that observed when survival was plotted against either biomarker alone (OS P = 2.1e −12 ; PFS P = 2.3e
−11
). In particular, we confirmed in this cohort of patients that, in tumors with both high miR-181a and high P-Smad2 expression, the median PFS was 10 months whereas, in patients with both low miR-181a-5p and P-Smad2, the median PFS was 22 months (OR = 12.5; 95% CI 5.6-27.9). Differences in OS were similar; patient tumors expressing high miR-181a-5p and P-Smad2 presented with a median OS of 16 months whereas, in patients with both low miR-181a-5p and P-Smad2, the median OS was 46.5 months (OR = 17.1; 95% CI 6.7-43.8). The PFS and OS for those patients with high miR181a-5p and low P-Smad2 or vice versa were not significant ( Figure 4B, lower panels) .
We next assessed whether concomitant expression of miR181a-5p and P-Smad2 was preferentially observed in tumor biopsies taken from patients with PFI > or <6 months or with residual tumor > or <1 cm. χ 2 -test analysis (supplementary Table S3 , available at Annals of Oncology online) revealed that co-expression of miR-181a-5p and P-Smad2 was more frequently observed in tumor biopsies taken from those patients with PFI <6 months than in tumor biopsies taken from those with PFI >6 months (P = 2.65e −8 ). Moreover, tumor biopsies taken from patients with a residual tumor of >1 cm had higher expression levels of miR-181a-5p and P-Smad2 than tumor biopsies taken from those with a residual tumor of <1 cm (P = 0.013, supplementary Table S3 , available at Annals of Oncology online).
Using Cox proportional multivariate survival model, we evaluated the best predictive covariates among those identified including let-7g-5p, miR-181a-5p, miR-199a-3p, miR-199a-5p, P-Smad2, clinical response to NACT and residual tumor after IDS. Table 3 shows that P-Smad2, miR-181a-5p and clinical response to NACT are the three covariates that most aptly identify the risk of patients relapse or death. let-7g-5p was associated with OS [hazard ratio (HR) 1.1, 95% CI 1.04-1.23, P = 0.0021], and residual tumor after IDS >1 cm was associated with PFS (HR 7.33, 95% CI 1.5-38.85, P = 0.01). No association was observed for the miR-199a family members (Table 3) .
discussion
In this study, the longitudinal analysis of the miRNA expression profile in HGS-EOC patients who received NACT helped to pinpoint miRNAs involved in the early mechanisms of Pt-based resistance that might be of potential clinical utility as biomarkers of poor prognosis. We gained two insights: (i) expression levels of miRNA let-7g-5p, miR-199a-3p, miR-199a-5p and miR181a-5p at diagnosis were independently associated with OS and PFS. (ii) Concomitant expression of P-Smad2 and miR181a-5p was related to poor prognosis, residual tumor after IDS and survival. This is, to our knowledge, the first study demonstrating, in matched HGS-EOC tumor biopsies, the expression levels of the above-mentioned four miRNAs associated with Ptresponse and prognosis. We observed that miR-181a-5p, miR199a-5p and miR-199a-3p were more expressed in tumors of patients with PFI <6 months, with residual tumor >1 cm, and their expression levels were associated to patients' survival. Characterization of the molecular mechanisms via which these four miRNAs might be involved in Pt-based resistance is beyond the scope of this work. Nevertheless, some hypotheses can be discussed taking into account the data published so far. The current knowledge of the roles of these miRNAs is limited [12] . However, Yang et al. identified a subset of miRNAs and genes that once integrated into a mesenchymal signature (IM) are associated with poorer prognosis in HGS-EOC than genes integrated into the epithelial signature (IE) [11] . miR-199 family members were upregulated in the IM signature compared with the IE signature. Our analysis is consistent with the notion that high tumor levels of miR-199 family members correlated with poor prognosis. Our group demonstrated that, in stage I tumor biopsies, the expression levels of miR-199a-3p and miR-199a-5p were associated with poor prognosis [13] . Thus, it is plausible to speculate that, although stage I and stage III represent different diseases, they share the same anatomical site of growth and proliferation (i.e. the ovary) as well as the molecular mechanisms which confer resistance against front-line Pt-based chemotherapy. Information on levels of let-7 members in HGS-EOC is unavailable. This is relevant as they have been suggested to act as tumor suppressors [12, 14, 15] . However, further analysis in independent validation sets is required to consider miR-199a-3p, miR-199a-5p, and let-7g-5p as prognostic markers for HGS-EOC. As far as the second insight, the association of concomitant expression of P-Smad2 and miR-181a-5p to poor prognosis, residual tumor after IDS and survival results confirms our previous preliminary findings, strengthening the potential clinical relevance of this miRNA. [7] . We have previously demonstrated that patients with high expression levels of miR-181a-5p at diagnosis relapsed within 6 months from the end of Pt-based therapy with a relatively short survival [7] . Instead, patients with low levels of miR-181a-5p relapsed after 6 months from the end of chemotherapy and had a good prognosis. As to the potential biological mechanisms, we demonstrated that miR-181a-5p controls the activity of the TGF-β pathway, by directly downregulating the expression levels of Smad-7, an intracellular inhibitor of TGF-β. In various in vitro and in vivo models, enhanced expression of miR-181a-5p led to increased cellular motility, dissemination and resistance to therapy, due to cellular transition from an epithelial state to a mesenchymal state (EMT). To demonstrate the role of miR-181a-5p and EMT in driving Pt resistance in relapsed tumors, expression levels of miR-181a-5p and of selected EMT markers were compared in a second and independent cohort of tumor biopsies, taken from patients before chemotherapy, when the tumor was Pt sensitive, and at relapse, after many lines of chemotherapy when the tumor had acquired resistance. Data from matched human biopsies mirrored the in vitro models: miR-181a-5p expression levels were increased in relapsed resistant tumors compared with paired primary sensitive tumors. The same results were obtained for the other markers associated with the EMT and controlled by the TGF-β receptor.
Although in this study biopsies came from NACT-treated patients, which is a quite different clinical situation from that previously described [7] , results strengthened our hypothesis that miR-181a-5p is an 'oncomiR' in HGS-EOC. By regulating the TGF-β pathway, miR-181a-5p confers a positive advantage to tumor cells to withstand Pt treatment.
One might hypothesize that, for biomarker identification within the complex and heterogeneous genetic background of HGS-EOC, pathway-based approaches may perform better than single-gene approaches. Our previous study revealed that combined genomic and proteomic analysis of biomarkers that Cox proportional hazards regression analysis of overall and progression-free survival for the 82 HGS-EOC patients is reported according to clinical variables described in Table 1 and molecular signatures previously identified. The hazard ratio (HR) is reported with its own 95% confidential interval (CI). regulate the EMT process provides a more functionally relevant prognostic signature than analysis of each biomarker alone [7] . In line with these data, KM curves combined by plotting the expression levels of both miR-181a-5p-known to increase the TGF-β signaling by shutting down the negative regulatory protein Smad-7-with the nuclear P-Smad2 protein-a nuclear protein that is phosphorylated upon activation of the TGF-β pathway-carried out better than curves considering the expression of each biomarker alone. In conclusion, since these findings represent a second independent validation of previous findings [7] , our data strongly indicate that at least two key elements of the TGF-β pathway, i.e. miR-181a-5p and P-Smad2, allow us to identify those patients who will not benefit from the standard protocols of Pt-based NACT and thus should be treated with novel investigational drugs or new combinations. The involvement of TGF-β and EMT in the resistance to conventional therapy provides a valid rational to investigate new drugs that target this pathway. 
